References analysis of the Wikipedia article "Methysergide" in the English version

doi.org

Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A (August 2013). "Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs". Expert Opinion on Pharmacotherapy. 14 (12): 1599–1610. doi:10.1517/14656566.2013.806487. PMID 23815106. S2CID 22721405.

Majrashi M, Ramesh S, Deruiter J, Mulabagal V, Pondugula S, Clark R, et al. (2017). "Multipotent and Poly-therapeutic Fungal Alkaloids of Claviceps purpurea". In Agrawal DC, Tsay HS, Shyur LF, Wu YC, Wang SY (eds.). Medicinal Plants and Fungi: Recent Advances in Research and Development. Medicinal and Aromatic Plants of the World. Vol. 4. pp. 229–252. doi:10.1007/978-981-10-5978-0_8. ISBN 978-981-10-5977-3. ISSN 2352-6831.

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, et al. (December 2000). "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications". Circulation. 102 (23): 2836–2841. doi:10.1161/01.cir.102.23.2836. PMID 11104741.

Guzman M, Armer T, Borland S, Fishman R, Leyden M (April 2020). "Novel Receptor Activity Mapping of Methysergide and its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine (2663)" (PDF). Neurology. 94 (15 Supplement): 2663. doi:10.1212/WNL.94.15_supplement.2663. S2CID 266103427. Archived from the original (PDF) on 2023-05-29.

Keller U, Tudzynski P (2002). "Ergot Alkaloids". Industrial Applications. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 157–181. doi:10.1007/978-3-662-10378-4_8. ISBN 978-3-642-07481-3.

Chen W, De Wit-Bos L (2020). Risk assessment of Argyreia nervosa (PDF) (Report). doi:10.21945/rivm-2019-0210.

Paulke A, Kremer C, Wunder C, Wurglics M, Schubert-Zsilavecz M, Toennes SW (April 2015). "Studies on the alkaloid composition of the Hawaiian Baby Woodrose Argyreia nervosa, a common legal high". Forensic Sci Int. 249: 281–293. doi:10.1016/j.forsciint.2015.02.011. PMID 25747328.

Doepfner W, Cerletti A (1958). "Comparison of lysergic acid derivatives and antihistamines as inhibitors of the edema provoked in the rat's paw by serotonin". Int Arch Allergy Appl Immunol. 12 (1–2): 89–97. doi:10.1159/000228445. PMID 13549054.

Sicuteri F (1959). "Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine". Int Arch Allergy Appl Immunol. 15 (4–5): 300–307. doi:10.1159/000229055. PMID 14446408.

Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR (November 1974). "Cardiac murmurs and endocardial fibrosis associated with methysergide therapy". Am Heart J. 88 (5): 640–655. doi:10.1016/0002-8703(74)90251-8. PMID 4420941.

Joseph T, Tam SK, Kamat BR, Mangion JR (April 2003). "Successful repair of aortic and mitral incompetence induced by methylsergide maleate: confirmation by intraoperative transesophageal echocardiography". Echocardiography. 20 (3): 283–287. doi:10.1046/j.1540-8175.2003.03027.x. PMID 12848667. S2CID 22513342.

MacGregor EA, Evers S (October 2017). "The role of methysergide in migraine and cluster headache treatment worldwide - A survey in members of the International Headache Society". Cephalalgia. 37 (11): 1106–1108. doi:10.1177/0333102416660551. PMID 27449673. S2CID 206521928.

Sporer KA (August 1995). "The serotonin syndrome. Implicated drugs, pathophysiology and management". Drug Safety. 13 (2): 94–104. doi:10.2165/00002018-199513020-00004. PMID 7576268. S2CID 19809259.

Silberstein SD (September 1998). "Methysergide". Cephalalgia. 18 (7): 421–435. doi:10.1046/j.1468-2982.1998.1807421.x. PMID 9793694.

Colpaert FC, Niemegeers CJ, Janssen PA (October 1979). "In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine antagonists". European Journal of Pharmacology. 58 (4): 505–509. doi:10.1016/0014-2999(79)90326-1. PMID 510385.

Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, et al. (August 2004). "Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 370 (2): 114–123. doi:10.1007/s00210-004-0951-4. PMID 15322733. S2CID 8938111.

Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, et al. (January 2000). "Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine". Molecular Pharmacology. 57 (1): 75–81. doi:10.1016/S0026-895X(24)26444-0. PMID 10617681.

Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, Tfelt-Hansen V (1 January 1986). "Pharmacokinetics of methysergide and its metabolite methylergometrine in man". European Journal of Clinical Pharmacology. 30 (1): 75–77. doi:10.1007/BF00614199. PMID 3709634. S2CID 9583732.

Ott J, Neely P (1980). "Entheogenic (hallucinogenic) effects of methylergonovine". Journal of Psychedelic Drugs. 12 (2): 165–166. doi:10.1080/02791072.1980.10471568. PMID 7420432.

Halberstadt AL, Nichols DE (2020). "Serotonin and serotonin receptors in hallucinogen action". Handbook of the Behavioral Neurobiology of Serotonin. Handbook of Behavioral Neuroscience. Vol. 31. pp. 843–863. doi:10.1016/B978-0-444-64125-0.00043-8. ISBN 978-0-444-64125-0. ISSN 1569-7339. S2CID 241134396.

Cavero I, Guillon JM (2014). "Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy". Journal of Pharmacological and Toxicological Methods. 69 (2): 150–161. doi:10.1016/j.vascn.2013.12.004. PMID 24361689.

Segelcke D, Messlinger K (April 2017). "Putative role of 5-HT2B receptors in migraine pathophysiology". Cephalalgia. 37 (4): 365–371. doi:10.1177/0333102416646760. PMID 27127104.

Dahlöf C, Maassen Van Den Brink A (April 2012). "Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment". Headache. 52 (4): 707–714. doi:10.1111/j.1526-4610.2012.02124.x. hdl:1765/73130. PMID 22444161. S2CID 29701226.

Newman-Tancredi A, Conte C, Chaput C, Verrièle L, Audinot-Bouchez V, Lochon S, et al. (June 1997). "Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy". Naunyn-Schmiedeberg's Archives of Pharmacology. 355 (6): 682–688. doi:10.1007/pl00005000. PMID 9205951. S2CID 24209214.

Koehler PJ, Tfelt-Hansen PC (November 2008). "History of methysergide in migraine". Cephalalgia. 28 (11): 1126–1135. doi:10.1111/j.1468-2982.2008.01648.x. PMID 18644039. S2CID 22433355.

1966 Webb AJ, Edwards PD (April 1966). "Methysergide and Retroperitoneal Fibrosis". British Medical Journal. 1 (5495): 1110. doi:10.1136/bmj.1.5495.1110-a. PMC 1844020.

Graham JR, Suby HI, LeCompte PR, Sadowsky NL (February 1966). "Fibrotic disorders associated with methysergide therapy for headache". The New England Journal of Medicine. 274 (7): 359–368. doi:10.1056/NEJM196602172740701. PMID 5903120.

in.gov.br

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

nih.gov

pubmed.ncbi.nlm.nih.gov

Silberstein SD (September 1998). "Methysergide". Cephalalgia. 18 (7): 421–435. doi:10.1046/j.1468-2982.1998.1807421.x. PMID 9793694.

Saxena PR, Lawang A (October 1985). "A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors". Archives Internationales de Pharmacodynamie et de Therapie. 277 (2): 235–252. PMID 2933009.

Ott J, Neely P (1980). "Entheogenic (hallucinogenic) effects of methylergonovine". Journal of Psychedelic Drugs. 12 (2): 165–166. doi:10.1080/02791072.1980.10471568. PMID 7420432.

Segelcke D, Messlinger K (April 2017). "Putative role of 5-HT2B receptors in migraine pathophysiology". Cephalalgia. 37 (4): 365–371. doi:10.1177/0333102416646760. PMID 27127104.

Koehler PJ, Tfelt-Hansen PC (November 2008). "History of methysergide in migraine". Cephalalgia. 28 (11): 1126–1135. doi:10.1111/j.1468-2982.2008.01648.x. PMID 18644039. S2CID 22433355.

pubchem.ncbi.nlm.nih.gov

"Methysergide". PubChem. U.S. National Library of Medicine.

"methysergide". PubChem. U.S. National Library of Medicine. Retrieved 2017-09-06.

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

Koehler PJ, Tfelt-Hansen PC (November 2008). "History of methysergide in migraine". Cephalalgia. 28 (11): 1126–1135. doi:10.1111/j.1468-2982.2008.01648.x. PMID 18644039. S2CID 22433355.

web.archive.org

worldcat.org

search.worldcat.org

Methysergide (English Wikipedia)

bindingdb.org

books.google.com

doi.org

drugpatentwatch.com

europa.eu

ema.europa.eu

handle.net

hdl.handle.net

in.gov.br

medscape.com

emedicine.medscape.com

migrainetrust.org

nih.gov

pubmed.ncbi.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

rivm.nl

semanticscholar.org

api.semanticscholar.org

tranquilene.com

unc.edu

pdsp.unc.edu

web.archive.org

worldcat.org

search.worldcat.org

xocpharma.com